{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:06:27Z","timestamp":1780463187547,"version":"3.54.1"},"reference-count":42,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:p>OBJECTIVE. Global eradication of poliomyelitis may soon be achieved, but circulating polioviruses could reemerge years after eradication by reversion of live attenuated oral vaccine virus to a virulent form, laboratory stock mishandling, or bioterrorism. If a poliomyelitis outbreak occurs in the United States, access to a vaccine stockpile to interrupt viral spread will be necessary. Options for the stockpile include the inactivated polio vaccine and the live-attenuated trivalent and monovalent oral poliovirus vaccines. With differences in immunogenicity, adverse effects, availability, and other issues, the optimal vaccine choice for the stockpile is not clear. We sought to compare vaccine interventions for poliomyelitis outbreak control.<\/jats:p><jats:p>DESIGN. We applied decision analysis to 8 strategies for outbreak control: no intervention, 1 or 2 inactivated polio vaccine doses, 1 or 2 trivalent oral poliovirus vaccine doses, 1 or 2 monovalent oral poliovirus vaccine doses, and sequential inactivated polio vaccine-monovalent oral poliovirus vaccine. Historical data from outbreaks in developed countries were used to estimate the risk of paralytic disease after a hypothetical reintroduction of circulating polioviruses. The outcome measure was cases of paralytic poliomyelitis.<\/jats:p><jats:p>RESULTS. Monovalent oral poliovirus vaccine provided optimal outbreak control in most scenarios because of high seroconversion rates with 1 dose. Control provided by trivalent oral poliovirus vaccine and inactivated polio vaccine was equivalent at high vaccine coverage rates. At low intervention rates, trivalent oral poliovirus vaccine produced fewer paralytic cases than inactivated polio vaccine in highly immune populations but more cases than inactivated polio vaccine in poorly immunized groups because of secondary transmission of oral poliovirus vaccine virus and vaccine-derived viruses.<\/jats:p><jats:p>CONCLUSIONS. This model suggests that monovalent oral poliovirus vaccine would be the most advantageous vaccine for outbreak control. If a monovalent oral poliovirus vaccine stockpile is impractical, the optimal vaccine choice depends on the previous immunity and the anticipated intervention rates.<\/jats:p>","DOI":"10.1542\/peds.2005-2358","type":"journal-article","created":{"date-parts":[[2006,8,2]],"date-time":"2006-08-02T17:07:56Z","timestamp":1154538476000},"page":"611-618","source":"Crossref","is-referenced-by-count":18,"title":["Decision Analysis in Planning for a Polio Outbreak in the United States"],"prefix":"10.1542","volume":"118","author":[{"given":"Pamela C.","family":"Jenkins","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Dartmouth Medical School, Hanover, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Modlin","sequence":"additional","affiliation":[{"name":"Children's Hospital at Dartmouth, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,8,1]]},"reference":[{"key":"2021120822423066600_R1","doi-asserted-by":"crossref","unstructured":"Roberts L. Polio: the final assault?Science.\u20082004;303:1960\u20131968","DOI":"10.1126\/science.303.5666.1960"},{"key":"2021120822423066600_R2","unstructured":"World Health Organization. Progress towards interruption of wild poliovirus transmission, January 2004 to March 2005. Week Epidemiol Rec.\u20082005;80:149\u2013156"},{"key":"2021120822423066600_R3","unstructured":"Centers for Disease Control and Prevention. Poliovirus infections in four unvaccinated children \u2013 Minnesota, August\u2013October 2005. MMWR Morb Mortal Wkly Rep.\u20082005;54:1053\u20131055"},{"key":"2021120822423066600_R4","unstructured":"World Health Organization. Wild poliovirus, 22 Feb 2005 to 21 Feb 2006. 21 February 2006. Available at: www.polioeradication.org\/content\/fixed\/casemap.shtml. Accessed February 27, 2006"},{"key":"2021120822423066600_R5","unstructured":"Aylward R, Cochi S. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull WHO.\u20082004;82:40\u201346"},{"key":"2021120822423066600_R6","doi-asserted-by":"crossref","unstructured":"Modlin J. Poliomyelitis in the United States: the final chapter?JAMA.\u20082004;292:1749\u20131751","DOI":"10.1001\/jama.292.14.1749"},{"key":"2021120822423066600_R7","doi-asserted-by":"crossref","unstructured":"Cello J, Paul A, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science.\u20082002;297:1016\u20131018","DOI":"10.1126\/science.1072266"},{"key":"2021120822423066600_R8","doi-asserted-by":"crossref","unstructured":"Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. \u201cEndgame\u201d issues for the global polio eradication initiative. Clin Infect Dis.\u20082002;34:72\u201377","DOI":"10.1086\/338262"},{"key":"2021120822423066600_R9","doi-asserted-by":"crossref","unstructured":"NVAC-ACIP Joint Working Group and Centers for Disease Control and Prevention. Ensuring preparedness for potential poliomyelitis outbreaks. Recommendations for the US Poliovirus Vaccine Stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Arch Ped Adol Med.\u20082004;158:1106\u20131112","DOI":"10.1001\/archpedi.158.12.1106"},{"key":"2021120822423066600_R10","unstructured":"Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. MMWR Morb Mort Wkly Rep.\u20082000;49:1\u201322"},{"key":"2021120822423066600_R11","doi-asserted-by":"crossref","unstructured":"Sutter R, Patriarca P, Suleiman A, et al. Attributable risk of DTP (diphtheria and tetanux toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. J Infect Dis.\u20081992;165:444\u2013449","DOI":"10.1093\/infdis\/165.3.444"},{"key":"2021120822423066600_R12","unstructured":"World Health Organization. Polio Outbreak Spreads Across Yemen. Available at: www.who.int\/mediacentre\/news\/releases\/2005\/pr19\/en\/index.html. Accessed May 6, 2005."},{"key":"2021120822423066600_R13","doi-asserted-by":"crossref","unstructured":"Caceres V, Sutter R. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis.\u20082001;33:531\u2013541","DOI":"10.1086\/321905"},{"key":"2021120822423066600_R14","doi-asserted-by":"crossref","unstructured":"Detsky A, Naigle G, Krahn M, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 \u2013 getting started. Med Decis Making.\u20081997;17:123\u2013125","DOI":"10.1177\/0272989X9701700201"},{"key":"2021120822423066600_R15","unstructured":"Weinstein M, Fineberg H. Clinical Decision Analysis. Philadelphia, PA: WB Saunders; 1980"},{"key":"2021120822423066600_R16","unstructured":"TreeAge Pro [computer program]. Williamstown, MA: TreeAge Software, Inc; 2005"},{"key":"2021120822423066600_R17","doi-asserted-by":"crossref","unstructured":"Oronato I, Modlin J, McBean A, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis.\u20081991;163:1\u20136","DOI":"10.1093\/infdis\/163.1.1"},{"key":"2021120822423066600_R18","doi-asserted-by":"crossref","unstructured":"Nishio O, Ishihara Y, Sakae K, Thoms ML, Losonsky GA, Bernier RH. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand.\u20081984;12:1\u201310","DOI":"10.1016\/S0092-1157(84)80015-3"},{"key":"2021120822423066600_R19","doi-asserted-by":"crossref","unstructured":"Kimball A, Barr R, Bauer H, Kleinman H, Johnson EA, Cooney MK. Community spread of orally administered attenuated poliovirus vaccine strains. Pub Health Rep.\u20081961;76:903\u2013914","DOI":"10.2307\/4591314"},{"key":"2021120822423066600_R20","doi-asserted-by":"crossref","unstructured":"Gelfand H, LeBlanc D, Potash L, Clemmer DI, Fox JP. The spread of living attenuated strains of polioviruses in 2 communities in southern Louisiana. Am J Public Health.\u20081960;50:767\u2013778","DOI":"10.2105\/AJPH.50.6_Pt_1.767"},{"key":"2021120822423066600_R21","unstructured":"Kew O, Wright P, Agol V, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull WHO.\u20082004;82:16\u201323"},{"key":"2021120822423066600_R22","doi-asserted-by":"crossref","unstructured":"Nkowane B, Wassilak S, Orenstein W, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA.\u20081987;257:1335\u20131340","DOI":"10.1001\/jama.257.10.1335"},{"key":"2021120822423066600_R23","unstructured":"Bijkerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand.\u20081979;43:195\u2013206"},{"key":"2021120822423066600_R24","unstructured":"Van Wijngaarden J, van Loon A. The polio epidemic in The Netherlands, 1992\/1993. Public Health Rev.\u20081994;21:107\u2013116"},{"key":"2021120822423066600_R25","doi-asserted-by":"crossref","unstructured":"McBean A, Thoms M, Albrecht P, et al. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epidemiol.\u20081988;128:615\u2013628","DOI":"10.1093\/oxfordjournals.aje.a115009"},{"key":"2021120822423066600_R26","doi-asserted-by":"crossref","unstructured":"Cohen-Abbo A, Culley B, Reed G, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Ped Infect Dis J.\u20081995;14:100\u2013106","DOI":"10.1097\/00006454-199502000-00004"},{"key":"2021120822423066600_R27","doi-asserted-by":"crossref","unstructured":"Patriarca P, Sutter R, Oostvogel P. Outbreaks of paralytic poliomyelitis, 1976\u20131995. J Infect Dis.\u20081997;175:S165\u2013S172","DOI":"10.1093\/infdis\/175.Supplement_1.S165"},{"key":"2021120822423066600_R28","unstructured":"Schaap G, Bijkerk H, Coutinho R, et al. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol.\u20081984;29:124\u2013140"},{"key":"2021120822423066600_R29","unstructured":"Centers for Disease Control and Prevention. National Immunization Program. Immunization coverage in the US. Available at: www.cdc.gov\/nip\/coverage\/default.htm#chart. Accessed September 15, 2004."},{"key":"2021120822423066600_R30","doi-asserted-by":"crossref","unstructured":"Prevots D, Pascual F, Angellili M, et al. Population immunity to polioviruses among preschool children from four urban low-income communities, United States, 1997\u20132001. Ped Infect Dis J.\u20082004;23:1130\u20131136","DOI":"10.1097\/01.inf.0000143641.27336.2e"},{"key":"2021120822423066600_R31","doi-asserted-by":"crossref","unstructured":"Tebbens R, Pallansch M, Kew O, et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol.\u20082005;162:358\u2013372","DOI":"10.1093\/aje\/kwi206"},{"key":"2021120822423066600_R32","unstructured":"World Health Organization. Polio Case Count. 16 February 2006. Available at: www.who.int\/vaccines\/immunization_monitoring\/en\/diseases\/poliomyelitis\/case_count.cfm. Accessed February 27, 2006"},{"key":"2021120822423066600_R33","doi-asserted-by":"crossref","unstructured":"Chen R, Hausinger S, Dajani A, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA.\u20081996;275:1639\u20131645","DOI":"10.1001\/jama.275.21.1639"},{"key":"2021120822423066600_R34","doi-asserted-by":"crossref","unstructured":"Modlin J, Halsey N, Thoms M, et al. Humoral and mucosal immunity in infants induced by three sequential IPV-OPV immunization schedules. J Infect Dis.\u20081997;75:S228\u2013S234","DOI":"10.1093\/infdis\/175.Supplement_1.S228"},{"key":"2021120822423066600_R35","doi-asserted-by":"crossref","unstructured":"Gelfand H, Fox J, LeBlanc D. Observations on natural poliovirus infection in immunized children. Am J Public Health.\u20081957;47:421\u2013431","DOI":"10.2105\/AJPH.47.4_Pt_1.421"},{"key":"2021120822423066600_R36","doi-asserted-by":"crossref","unstructured":"Gelfand H, LeBlanc D, Potash L, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg.\u20081959;70:312\u2013327","DOI":"10.1093\/oxfordjournals.aje.a120080"},{"key":"2021120822423066600_R37","doi-asserted-by":"crossref","unstructured":"Gelfand H, LeBlanc D, Fox J, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg.\u20081957;65:367\u2013385","DOI":"10.1093\/oxfordjournals.aje.a119876"},{"key":"2021120822423066600_R38","doi-asserted-by":"crossref","unstructured":"Melnick J, Ledinko N. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am J Hyg.\u20081951;54:354\u2013382","DOI":"10.1093\/oxfordjournals.aje.a119492"},{"key":"2021120822423066600_R39","doi-asserted-by":"crossref","unstructured":"Horstmann D. Clinical aspects of acute poliomyelitis. Am J Med.\u20081949;6:592","DOI":"10.1016\/0002-9343(49)90132-1"},{"key":"2021120822423066600_R40","doi-asserted-by":"crossref","unstructured":"Prevots D, Sutter R, Strebel P, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch Ped Adol Med.\u20081994;148:479\u2013485","DOI":"10.1001\/archpedi.1994.02170050037007"},{"key":"2021120822423066600_R41","doi-asserted-by":"crossref","unstructured":"Alexander L, Seward J, Santibanez T, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA.\u20082004;292:1696\u20131701","DOI":"10.1001\/jama.292.14.1696"},{"key":"2021120822423066600_R42","doi-asserted-by":"crossref","unstructured":"Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959\u20131982. Rev Infect Dis.\u20081984;6(suppl 2):S413\u2013S418","DOI":"10.1093\/clinids\/6.Supplement_2.S413"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/2\/611\/1074139\/zpe00806000611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/2\/611\/1074139\/zpe00806000611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:17:50Z","timestamp":1683544670000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/2\/611\/69045\/Decision-Analysis-in-Planning-for-a-Polio-Outbreak"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,8,1]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-2358","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}